Assessing disease burden in patients with classic MPNs.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.

CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.

Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort.

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Ruxolitinib for myelofibrosis--an update of its clinical effects.

The new landscape of therapy for myelofibrosis.